High absorption cream is an industry first,
meeting patient needs
MARKHAM, ON, Oct. 4, 2017 /CNW/ - MedReleaf Corp. (TSX:LEAF)
("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP
certified producer of medical cannabis, today announced the launch
of a topical cream, the first Canadian Licensed Producer to do so.
The cream is specifically formulated to provide superior absorption
with MedReleaf's award-winning high CBD strain and was developed in
response to patient feedback for topical applications of CBD.
MedReleaf Topical Cream mixes and integrates with the cannabis oil
to create an easy-to-use topical agent for direct application to
affected areas.
"Our product development team has devised a method to provide
Canadian patients with a much sought-after, high-absorption,
topical cream that is within the strict limitations afforded by the
current regulations," said Neil
Closner, CEO of MedReleaf. "This is further evidence of
MedReleaf's continued leadership in setting the standard for
product innovation and focus on the patient experience."
"The Dermatology community is very intrigued and excited about
the potential benefits of cannabinoids including Cannabidiol (CBD)
in treating a variety of skin ailments," said Dr. Jaggi Rao, MD, Board Certified Dermatologist,
and Clinical Professor of Medicine at the University of Alberta. "These novel agents could
offer significant relief to patients suffering from pain and itch
in a number of inflammatory dermatoses. They have already
demonstrated anti-inflammatory benefits in muscle and joint
disorders, and the translation of this success to skin diseases is
only logical."
Topicals are seeing strong growth in US markets with a tripling
of sales since 2014 and forecasts indicating a further tripling of
sales by 2019, according to the Brightfield Group. MedReleaf's
topical cream uses cosmetic grade ingredients; is approved by
Health Canada for sale; and is currently available at a special
introductory price to allow as many patients as possible to
experience this exciting new product. The suggested concentration
of cannabis in MedReleaf's mixed lotion is substantially more than
any equivalent products currently available in the US market. Easy
to follow instructions are included to allow for easy mixing of the
cream with our cannabis oil in order to enable use almost
immediately. The product is available now. Visit
medreleaf.com/cream for more information.
About MedReleaf Corp.
MedReleaf sets The Medical Grade
Standard™ for cannabis in Canada and around the world. The first
and only ICH-GMP and ISO 9001 certified cannabis producer in
North America, MedReleaf is a
R&D-driven company dedicated to patient care, scientific
innovation, research and advancing the understanding of the
therapeutic benefits of cannabis. Sourced from around the
world and perfected in one of two state of the art facilities in
Ontario, MedReleaf delivers a
variety of premium products to patients seeking safe, consistent
and effective medical cannabis.
For more information on MedReleaf, its products, research and
how the company is helping patients #livefree, please visit
MedReleaf.com or follow @medreleaf
Forward Looking Statements
This press release contains "forward-looking information" within
the meaning of applicable Canadian securities legislation which are
based upon MedReleaf's current internal expectations, estimates,
projections, assumptions and beliefs and views of future events.
Forward-looking information can be identified by the use of
forward-looking terminology such as "expect", "likely", "may",
"will", "should", "intend", "anticipate", "potential", "proposed",
"estimate" and other similar words, including negative and
grammatical variations thereof, or statements that certain events
or conditions "may", "would" or "will" happen, or by discussions of
strategy. Forward-looking information include estimates, plans,
expectations, opinions, forecasts, projections, targets, guidance
or other statements that are not statements of fact.
Any forward-looking information speaks only as of the date on
which it is made, and, except as required by law, MedReleaf does
not undertake any obligation to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise. New factors emerge from
time to time, and it is not possible for MedReleaf to predict all
such factors. When considering these forward-looking statements,
readers should keep in mind the risk factors and other cautionary
statements in MedReleaf's Annual Information Form dated
June 27, 2017 and filed with the
applicable Canadian securities regulatory authorities on SEDAR at
www.sedar.com. The risk factors and other factors noted in
MedReleaf's Annual Information Form could cause actual events or
results to differ materially from those described in any
forward-looking information.
SOURCE MedReleaf Corp.